Search clinical trials for: hypomethylating agent

Total 189253 results

The First Affiliated Hospital of Soochow University

Recruiting

Maintenance Therapy of Hypomethylating Agent (HMA) in Favorable Risk Acute Myeloid Leukemia (AML) Patients

Acute Myeloid Leukemia

China
National Cancer Institute (NCI)

Recruiting

Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes

Myelodysplastic Syndromes

United States
Shanghai General Hospital, Shanghai Jiao Tong University...

Recruiting

Hypomethylating Agent and Venetoclax After Allo-HSCT in Patients With High-risk Myeloid Malignancies.

Myeloid Malignancy | Venetoclax | Hypomethylating Agent

China
University of Florida

Not yet recruiting

Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction

Acute Myeloid Leukemia | Myelodysplastic Syndromes
Joshua Zeidner
University of North Carolina, Chapel Hill; Stemline Therapeutics, Inc.

Recruiting

Tagraxofusp and Azaxitadine With or Without Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents (TAGALONG)

Acute Myeloid Leukemia

United States
M.D. Anderson Cancer Center

Recruiting

A Phase II Study of Vibecotamab (XmAb14045) for MRD- Positive AML and MDS After Hypomethylating Agent Failure

AML | MDS

United States
Affiliated Hospital to Academy of Military Medical...

Recruiting

Hypomemylating Agents Combination With eDC Therapy for Elderly Patients With Myelodysplastic Syndrome (eDC-MDS)

Myelodysplastic Syndromes | Immunotherapy | Dendritic Cell | Hypomethylating Agents

China
Brian Jonas
National Cancer Institute (NCI); AbbVie

Recruiting

Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure

Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia

United States
Gruppo Italiano Malattie EMatologiche dell'Adulto

Recruiting

Prospective and Retrospective Observational Evaluation of Real World Outcome of Unfit AML Patients Treated With the Combination Venetoclax Plus Hypomethylating Agents, Under the Italian Law No.648/96

Acute Myeloid Leukemia

Italy
Beijing Tongren Hospital

Recruiting

Sintilimab and Decitabine for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma

Extranodal NK/T-cell Lymphoma

China
Kirsten Grønbæk
Odense University Hospital; Karolinska University Hospital; Zealand University... and other collaborators

Recruiting

Combining Active and Passive DNA Hypomethylation (EVI-3)

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia

Denmark, Sweden
Case Comprehensive Cancer Center

Recruiting

CPX-351 Therapy for MDS After Hypomethylating Agent Failure

Myelodysplastic Syndrome (MDS)

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Fostamatinib for the Treatment of Lower-risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia Who Have Failed Therapy With Hypomethylating Agents

Refractory Chronic Myelomonocytic Leukemia | Refractory Myelodysplastic Syndrome

United States
Novartis Pharmaceuticals

Active, not recruiting

A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS). (STIMULUS-MDS1)

Myelodysplastic Syndromes

Czechia, Hungary, Japan, Taiwan, United States, Belgium, Italy, United Kingdom, Korea, Republic of, Hong Kong, Austria, Germany, Turkey, Spain, Greece, France, Canada
Arbeitsgemeinschaft medikamentoese Tumortherapie

Completed

Registry on Hypomethylating Agents in Myeloid Neoplasms

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia

Austria, Croatia
National Cancer Institute (NCI)

Active, not recruiting

Testing the Safety and Efficacy of the Combination of the Antibody Pembrolizumab and Entinostat in Patients With Myelodysplastic Syndrome Who Are Not Responding to Hypomethylating Agents

Myelodysplastic Syndrome

United States
Celgene

Completed

Safety and Efficacy Study of CC-486 in Subjects With Myelodysplastic Syndromes

Myelodysplastic Syndromes

United States, United Kingdom, Australia, Poland, Spain, Belgium, Italy, Germany, France, Canada
Fred Hutchinson Cancer Center

Completed

Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant (ICT-HCT)

Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | Secondary Myelodysplastic Syndrome | de Novo Myelodysplastic Syndrome

United States
Sumitomo Pharma America, Inc.

Terminated

A Phase 1b/2 Study of Alvocidib Plus Decitabine or Azacitidine in Patients With MDS

Myelodysplastic Syndromes (MDS)

United States
National Cancer Institute (NCI)

Terminated

Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas

Carcinoma, Non-Small-Cell Lung | Non-Small Cell Lung Cancer | Lung Cancer | Carcinoma, Esophageal | Malignant Pleural Mesotheliomas

United States
The Cleveland Clinic
Celgene

Withdrawn

DNA Hypomethylating Agents and Lenalidomide in Elderly Patients With Myeloid Malignancies in the US

Acute Myeloid Leukemia | Myelodysplastic Syndromes

United States
Celgene

Active, not recruiting

Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

United States, Italy, France, Germany, Greece, Spain
Xennials Therapeutics Australia Pty Ltd
Pinotbio, Inc.

Terminated

NTX-301 Monotherapy in Advanced Solid Tumours and in Combination With Platinum-based Chemotherapy in Advanced Ovarian & Bladder Cancer and in Combination With Temozolomide in High-grade Glioma

Advanced Solid Tumor | High-grade Glioma | Platinum-Resistant Ovarian Cancer | Platinum-Resistant Urothelial Carcinoma

Australia
Ehab L Atallah

Completed

Hypomethylating Properties of Freeze-dried Black Raspberries (BRB) in Patients With Myelodysplastic Syndrome or Myelodysplastic Syndrome/Myeloproliferative Neoplasm (MDS/MPN)

Myelodysplastic Syndromes

United States
M.D. Anderson Cancer Center
MDS Clinical Research Consortium

Completed

Interventional Validation of an MDS-Specific Measure of Quality of Life: Assessing the Responsiveness of the Quality of Life in Myelodysplasia Scale (QUALMS-1) to Different Hypomethylating Agent Regimens for Low and Intermediate Risk Disease

Leukemia

United States
Yale University

Withdrawn

CPX-351 in Patients Treated for Higher-risk Myelodysplastic Syndromes Experiencing Hypomethylating Agent Failure.

MDS

United States
M.D. Anderson Cancer Center
Teva Pharmaceuticals USA

Completed

Omacetaxine in Patients With Intermediate-1 and Higher Risk Myelodysplastic Syndrome (MDS) Post Hypomethylating Agent (HMA) Failure

Leukemia

United States
Astex Pharmaceuticals, Inc.

Completed

SGI-110 in Patients With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)

AML | MDS | CMML

United States, Canada
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Withdrawn

CPI-613 and Hydroxychloroquine for Patients With High Risk Myelodysplastic Syndrome

Myelodysplastic Syndromes | Progressive Disease

United States
Istituto Scientifico Romagnolo per lo Studio e...

Unknown

Exploring Disease Immunogenicity and the Immunological Effects of Hypomethylating Agents in Acute Myeloid Leukemia (Immune-AML)

Acute Myeloid Leukemia

Italy
Astex Pharmaceuticals, Inc.

Completed

SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction

Leukemia, Myeloid, Acute

United States, Spain, Korea, Republic of, Taiwan, Australia, Canada, Denmark, Hungary, Japan, Finland, Italy, Serbia, Czechia, France, Germany, Sweden, Netherlands, Poland, Russian Federation, Austria, United Kingdom, Romania, Belgium, Bulgar...
Nasser Hanna

Completed

Study of the Hypomethylating Drug Guadecitabine (SGI-110) Plus Cisplatin in Relapsed Refractory Germ Cell Tumors

Testis Cancer | Testicular Cancer | Germ Cell Tumor

United States
Ospedale Maggiore Di Trieste

Unknown

Hypomethylating Agents and Venetoclax in Newly Diagnosed Acute Myeloid Leukemia Patients Not Eligible for Intensive Chemotherapy

Acute Myeloid Leukemia, Adult | Hypomethylating Agents | Venetoclax

Italy
Chinese PLA General Hospital

Unknown

Combined Inhibition of PD-1 and DNA Hypomethylating Agent +/- Chemotherapy in High-risk AML or Elderly Patients With AML Who Are Unfit for Intensive Chemotherapy

Acute Myeloid Leukemia, in Relapsed or Refractory | Acute Myeloid Leukemia, Elderly, Unfit | Acute Myeloid Leukemia With Positive Minimal Residual Disease

China
Novartis Pharmaceuticals

Completed

A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML).

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia

Belgium, Hungary, Spain, Germany, Canada, Switzerland, Thailand, Korea, Republic of, United Kingdom, Italy, Austria, Sweden, France, United States
M.D. Anderson Cancer Center
GlaxoSmithKline; Novartis

Completed

Eltrombopag With or Without Hypomethylating Agent After Hypomethylating Agent Failure For Patients With Myelodysplastic Syndrome (MDS)

Leukemia

United States
Celgene

Completed

Study With Azacitidine in Pediatric Subjects With Newly Diagnosed Advanced Myelodysplastic Syndrome (MDS) and Juvenile Myelomonocytic Leukemia (JMML)

Leukemia, Myelomonocytic, Juvenile | Myelodysplastic Syndrome

Spain, Germany, Italy, United Kingdom, Belgium, France, Denmark, Netherlands, Sweden, Switzerland, Austria, Czechia, Ireland
GlaxoSmithKline
Parexel

Terminated

Safety, Clinical Activity, Pharmacokinetics (PK) and Pharmacodynamics Study of GSK2879552, Alone or With Azacitidine, in Subjects With High Risk Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes | Myelodysplastic Syndrome

United States, Spain
University of Southern California
National Cancer Institute (NCI)

Terminated

Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or Refractory Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Patients Previously Treated With a Hypomethylating Agent

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia | Previously Treated Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes | Recurrent Adult Acute Myeloid Leukemia

United States
Weill Medical College of Cornell University
Sunesis Pharmaceuticals

Completed

Vosaroxin for Intermediate 2 or High-risk MDS After Failure With Hypomethylating Agent-based Therapy

Myelodysplastic Syndrome

United States
GWT-TUD GmbH

Terminated

Single Agent JNJ-56022473 in MDS and AML Patients FAILING HYPOMETHYLATING AGENT BASED THERAPY (SAMBA)

Acute Myeloid Leukemia (AML) | Myelodysplastic Syndrome (MDS)

France, Germany
Amgen

Completed

Determination of Safe and Effective Dose of Romiplostim (AMG 531) in Subjects With Myelodysplastic Syndrome (MDS)Receiving Hypomethylating Agents

Myelodysplastic Syndromes | Thrombocytopenia | MDS
Nanfang Hospital of Southern Medical University

Unknown

HMA+DLI vs DLI Preemptive Therapy Based on MRD for AL Undergoing Allo-HSCT

Minimal Residual Disease,Acute Leukemia, Hypomethylating Agents, Donor Lymphocyte Infusion, Allogeneic Hematopoietic Cell Transplantation

China
University of Utah
Genzyme, a Sanofi Company

Terminated

Low-dose Oral Clofarabine for the Treatment of IPSS INT-1, INT-2 or HIGH Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia

Cancer | Chronic Myelomonocytic Leukemia

United States
Helsinn Healthcare SA

Completed

Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA (MEI-005)

Myelodysplastic Syndrome | MDS

United States
Cornerstone Pharmaceuticals

Withdrawn

Safety and Effectiveness Study of CPI-613 to Treat Refractory or Relapsed Leukemia and Myelodysplastic Syndrome

Acute Myeloid Leukemia (AML) | Myelodysplastic Syndrome (MDS)

United States
Ulsan University Hospital
Cooperative Study Group A for Hematology

Unknown

Lenalidomide After Failure of Hypomethylating Agents in Myelodysplastic Syndrome (VIOLET)

Myelodysplastic Syndrome

Korea, Republic of
Washington University School of Medicine

Completed

Lenalidomide for Myelodysplastic Syndrome Refractory to Hypomethylating Agents

Myelodysplastic Syndromes

United States
Janssen Korea, Ltd., Korea

Completed

An Observational Study for Dacogen Long-Term Treatment in Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes

Korea, Republic of
M.D. Anderson Cancer Center
Eisai Inc.

Completed

A Study of Low-Dose Decitabine in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL)

Acute Lymphocytic Leukemia

United States

Search clinical trials for: hypomethylating agent

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ethiopia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations